FDA Rejects Melanoma Drug, Sparking Outcry Over 'Broken' System and Stifled Innovation

WOBURN, MA – April 10, 2026 – The U.S. Food and Drug Administration has delivered a stunning blow to Replimune Group, Inc., rejecting its promising melanoma therapy RP1 for the second time and triggering a fierce debate over the agency's consistency and its impact on medical innovation. In response to the decision, the Woburn-based biotech firm announced it would halt the drug's development, eliminate jobs, and scale back U.S. manufacturing, declaring the treatment "not viable" without timely approval.

The company received a Complete Response Letter (CRL) from the FDA, formally denying its Biologics License Application for RP1 used in combination with nivolumab for advanced melanoma patients who have stopped responding to other immunotherapies. The decision has left patients with limited options without a potential new lifeline and has sent shockwaves through the biotech industry, raising critical questions about the reliability of the FDA's accelerated approval pathway.

A System in Crisis, A Company in Turmoil

In a blistering rebuke of the regulatory process, Replimune's leadership did not mince words. The company stated it "disagrees with the FDA" and expressed profound disappointment that the agency failed to exercise "regulatory flexibility" for a patient population with dire unmet needs.

"It is deeply disappointing that the FDA has not exercised regulatory flexibility to meet patients’ needs given the data supporting strong efficacy and the favorable safety profile," said Sushil Patel, Ph.D., CEO of Replimune. "A treatment desperately needed by patients will not be available. Not because the medicine failed. Because the system did."

Patel described a "fragmented and slow-moving regulatory process" with "inconsistent communication" that he claims puts U.S. innovation at risk. The company alleges that after its first rejection in July 2025, a new FDA review team was appointed for the resubmission, replacing the team that had previously interacted with the company and granted the drug its Breakthrough Therapy Designation. According to Replimune, this new team did not meet with the company during the latest review cycle despite offers to do so.

Adding fuel to the fire, Replimune's press release included a remarkable claim, stating that a senior member of the prior FDA review team had publicly said the "BLA clinical team thought the applicant had provided adequate evidence to support contribution of effect of RP1 plus nivolumab but leadership did not agree." This suggests a significant internal disagreement within the FDA itself over the drug's merits, a detail that has intensified scrutiny of the final decision.

A Showdown Over Scientific Evidence

At the heart of the dispute is a fundamental disagreement over what constitutes "sufficient" evidence for approval. RP1 is an oncolytic immunotherapy, a novel approach that uses a genetically engineered herpes simplex virus to selectively kill cancer cells and stimulate a broader immune response.

Data from the company's single-arm IGNYTE trial, which formed the basis of the application, showed that among patients with advanced melanoma who had already progressed on standard anti-PD-1 therapy, treatment with RP1 and nivolumab yielded a 34% response rate. For those who responded, the effect was remarkably durable, with a median duration of 24.8 months.

Replimune argues that these results, which led the FDA to grant RP1 both Breakthrough Therapy Designation and Priority Review, were compelling enough for an accelerated approval. The company points to prior meetings, including a March 2021 Type B meeting, where it claims the FDA suggested a single-arm trial could be acceptable if the data was strong. The company also asserts that at a subsequent pre-BLA meeting, the FDA "did not object" to its plan to submit the application based on the IGNYTE trial data.

However, the FDA's CRL indicates the agency ultimately found the evidence insufficient. While the agency has not commented publicly beyond the CRL, such letters typically detail scientific and regulatory deficiencies. Research into the decision indicates the FDA was concerned that the single-arm trial design made it impossible to definitively prove the "contribution of effect"—that is, to isolate how much of the benefit came from RP1 versus the nivolumab it was paired with. The agency also reportedly raised concerns about the heterogeneity of the patient population and the methodology for assessing tumor response, which could confound the results.

The Human and Financial Fallout

The immediate consequences of the FDA's decision are severe. For Replimune, the rejection has been catastrophic. The company announced it has "no choice but to eliminate jobs, including substantially scaling back our U.S. based manufacturing operations." The news caused its stock (NASDAQ: REPL) to plummet, wiping out significant market value and jeopardizing the company's financial stability.

More importantly, the decision closes a door for thousands of patients. Melanoma is the fifth most common cancer in the United States, and while immunotherapy has transformed treatment, about half of patients either don't respond or eventually see their cancer progress. An estimated 8,500 Americans die from the disease each year, highlighting the urgent need for new options for this exact patient group.

"Patients and caregivers pleaded for urgency," Patel noted in his statement. "All of it was met with inconsistent communication."

Chilling Effect on the Accelerated Approval Pathway

Beyond Replimune and melanoma patients, the verdict on RP1 raises broader concerns about the future of drug development in the U.S. The FDA's Accelerated Approval pathway was created to speed promising therapies for serious diseases to patients based on early but compelling data, with a requirement for later confirmatory trials. This pathway is a lifeblood for the biotech industry, particularly in oncology, where it allows smaller, innovative companies to bring forward novel treatments without the time and immense expense of a full Phase 3 trial upfront.

The rejection of a drug that had received Breakthrough Therapy Designation—a status reserved for therapies showing substantial improvement over available options—sends a worrying signal to other developers and their investors. It suggests a higher, and perhaps less predictable, bar for approval. This regulatory uncertainty could dampen investment in novel platforms and discourage companies from pursuing the very innovations the pathway was designed to foster, potentially leaving the next generation of breakthrough therapies on the laboratory shelf.